Merlin C Thomas

List of Publications by Year in Descending Order

175 papers	9,183 citations	49 h-index	93 g-index
180 ext. papers	10,534 ext. citations	6.5 avg, IF	6.18 L-index

#	Paper	IF	Citations
175	Circulating Soluble ACE2 Plays an Independent Role to Protect against Vascular Damage in Diabetic Mice. *Antioxidants*, **2022**, 11, 987	7.1	1
174	Targeting the Pathobiology of Diabetic Kidney Disease.. *Advances in Chronic Kidney Disease*, **2021**, 28, 282-289	4.7	1
173	Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice. *Current Cardiology Reviews*, **2021**, 17, e160721187934	2.4	0
172	Severe acute respiratory syndrome coronavirus 2 as a potential cause of type 1 diabetes facilitated by spike protein receptor binding domain attachment to human islet cells: An illustrative case study and experimental data. *Diabetic Medicine*, **2021**, 38, e14608	3.5	3
171	Dimeric phosphorylation of glyoxalase I alters its symmetry and substrate binding mechanism: simulation studies. *Journal of Biomolecular Structure and Dynamics*, **2021**, 1-15	3.6	
170	Dietary intake and hospitalisation due to diabetic ketoacidosis and hypoglycaemia in individuals with type 1 diabetes. *Scientific Reports*, **2021**, 11, 1638	4.9	2
169	Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes. *Diabetologia*, **2020**, 63, 1424-1434	10.3	8
168	Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis. *Circulation Research*, **2020**, 127, 877-892	15.7	35
167	Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan. *Trials*, **2020**, 21, 459	2.8	5
166	Dicarbonyl-mediated AGEing and diabetic kidney disease. *Journal of Nephrology*, **2020**, 33, 909-915	4.8	7
165	Forensic interrogation of diabetic endothelitis in cardiovascular diseases and clinical translation in heart failure. *World Journal of Cardiology*, **2020**, 12, 409-418	2.1	2
164	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. *Contemporary Clinical Trials*, **2020**, 90, 105892	2.3	13
163	The Long-Term Incidence of Hospitalization for Ketoacidosis in Adults with Established T1D-A Prospective Cohort Study. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	4
162	Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. *Gut*, **2020**, 69, 841-851	19.2	114
161	The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. *Therapeutic Advances in Gastroenterology*, **2019**, 12, 1756284818822566	4.7	18
160	Perspectives On Optimizing Chronic Heart Failure Care Beyond Randomised Controlled Trials - What do we Consolidate and how do we Plan for the Future?. *Current Cardiology Reviews*, **2019**, 15, 158-160	2.4	
159	Non-invasive Risk Stratification for Coronary Artery Disease: Is It Time for Subclassifications?. *Current Cardiology Reports*, **2019**, 21, 87	4.2	3

158	Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. *Journal of Clinical Investigation*, **2019**, 129, 406-421	15.9	39
157	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis. *Diabetes*, **2018**, 67, 960-973	0.9	9
156	Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks. *Diabetes Care*, **2018**, 41, 748-754	14.6	17
155	Effects of Diabetes Medications Targeting the Incretin System on the Kidney. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 321-323	6.9	10
154	The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. *Diabetologia*, **2018**, 61, 2098-2107	10.3	125
153	: Type 2 Diabetes and Readmission for Heart Failure. *Clinical Medicine Insights: Cardiology*, **2018**, 12, 117954681877958	5.2	8
152	Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. *Journal of the American Heart Association*, **2018**, 7,	6	19
151	Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2759-2767	6.7	21
150	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. *Diabetes and Metabolism*, **2017**, 43 Suppl 1, 2S20-2S27	5.4	41
149	Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 2195-2203	9.4	48
148	A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. *Clinical Medicine Insights: Cardiology*, **2016**, 10, 163-171	3.2	3
147	Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. *Nature Reviews Nephrology*, **2016**, 12, 73-81	14.9	277
146	Epigenetic Mechanisms in Diabetic Kidney Disease. *Current Diabetes Reports*, **2016**, 16, 31	5.6	28
145	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. *Diabetes*, **2016**, 65, 1085-98	0.9	34
144	Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines. *Current Cardiology Reviews*, **2016**, 12, 166-79	2.4	1
143	Phase 4 Studies in Heart Failure - What is Done and What is Needed?. *Current Cardiology Reviews*, **2016**, 12, 216-30	2.4	12
142	Contextualizing Genetics for Regional Heart Failure Care. *Current Cardiology Reviews*, **2016**, 12, 231-42	2.4	7
141	Type 2 Diabetes and Heart Failure: Challenges and Solutions. *Current Cardiology Reviews*, **2016**, 12, 249-55	2.4	42

140	Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*, **2016**, 7, 439-54	3.6	22
139	AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. *Hypertension*, **2015**, 65, 1073-81	8.5	49
138	Northern Territory perspectives on heart failure with comorbidities understanding trial validity and exploring collaborative opportunities to broaden the evidence base. *Heart Lung and Circulation*, **2015**, 24, 536-43	1.8	10
137	Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. *Diabetes Care*, **2015**, 38, 1891-7	14.6	48
136	Diabetic kidney disease. *Nature Reviews Disease Primers*, **2015**, 1, 15018	51.1	241
135	ACE2 deficiency shifts energy metabolism towards glucose utilization. *Metabolism: Clinical and Experimental*, **2015**, 64, 406-15	12.7	32
134	Origin of the Y chromosome influences intrarenal vascular responsiveness to angiotensin I and angiotensin (1-7) in stroke-prone spontaneously hypertensive rats. *Hypertension*, **2014**, 64, 1376-83	8.5	7
133	Transforming growth factor- -mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. *Kidney International*, **2014**, 85, 352-61	9.9	137
132	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. *Molecular and Cellular Endocrinology*, **2014**, 394, 13-20	4.4	36
131	Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. *Diabetes Care*, **2014**, 37, 2593-600	14.6	48
130	Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. *Advances in Chronic Kidney Disease*, **2014**, 21, 311-7	4.7	27
129	Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. *Atherosclerosis*, **2014**, 235, 444-8	3.1	24
128	Preventing Progression of Chronic Kidney Disease: Renin Angiotensin Aldosterone System Blockade Beyond Blood Pressure **2014**, 123-134		
127	Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. *American Journal of Physiology - Renal Physiology*, **2014**, 306, F773-80	4.3	25
126	Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. *Clinical Science*, **2014**, 127, 485-97	6.5	26
125	Relationship between urinary sodium excretion over time and mortality in type 2 diabetes. *Diabetes Care*, **2014**, 37, e62-3	14.6	11
124	Added value of soluble tumor necrosis factor- eceptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. *Diabetes Care*, **2014**, 37, 2334-42	14.6	34
123	Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. *Diabetes*, **2014**, 63, 3915-25	0.9	64

122	Renal effects of dapagliflozin in patients with type 2 diabetes. *Therapeutic Advances in Endocrinology and Metabolism*, **2014**, 5, 53-61	4.5	42
121	Preventing Progression of Chronic Kidney Disease: Diet and Lifestyle **2014**, 113-122		
120	Coeliac disease, gluten-free diet and the development and progression of albuminuria in children with type 1 diabetes. *Pediatric Diabetes*, **2013**, 14, 455-8	3.6	11
119	Angiotensin converting enzyme 2 and atherosclerosis. *Atherosclerosis*, **2013**, 226, 3-8	3.1	39
118	The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes. *Diabetes and Metabolism*, **2013**, 39, 290-8	5.4	26
117	Diabetic kidney disease: new treatment options. *Diabetes Management*, **2013**, 3, 123-130	0	
116	Emerging drugs for managing kidney disease in patients with diabetes. *Expert Opinion on Emerging Drugs*, **2013**, 18, 55-70	3.7	7
115	Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with Type 1 diabetes. *Clinical Science*, **2013**, 124, 617-26	6.5	13
114	Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. *Diabetes Care*, **2013**, 36, 1827-33	14.6	33
113	Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 1782-92	12.7	20
112	Diabetes: Assessing renal risk in patients with type 2 diabetes. *Nature Reviews Nephrology*, **2013**, 9, 559-60	4.9	4
111	Does a nephron deficit exacerbate the renal and cardiovascular effects of obesity?. *PLoS ONE*, **2013**, 8, e73095	3.7	9
110	Post-translational modification of plant-made foreign proteins; glycosylation and beyond. *Biotechnology Advances*, **2012**, 30, 410-8	17.8	63
109	Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. *Diabetes*, **2012**, 61, 2105-13	0.9	50
108	Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. *Hypertension*, **2012**, 60, 98-105	8.5	41
107	Nutrient sensing, autophagy, and diabetic nephropathy. *Diabetes*, **2012**, 61, 23-9	0.9	125
106	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. *Clinical Science*, **2012**, 123, 547-55	6.5	41
105	Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy?. *Diabetologia*, **2012**, 55, 1505-13	10.3	28

104	Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7). *Clinical Science*, **2012**, 123, 29-37	6.5	24
103	High nephron endowment protects against salt-induced hypertension. *American Journal of Physiology - Renal Physiology*, **2012**, 303, F253-8	4.3	15
102	Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. *Clinical Science*, **2012**, 123, 519-29	6.5	40
101	The arterial depressor response to chronic low-dose angiotensin II infusion in female rats is estrogen dependent. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2012**, 302, R159-65	3.2	50
100	Towards understanding the inherited susceptibility for nephropathy in diabetes. *Current Opinion in Nephrology and Hypertension*, **2012**, 21, 195-202	3.5	41
99	Suppression of microRNA-29 expression by TGF-β promotes collagen expression and renal fibrosis. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 252-65	12.7	385
98	Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. *Circulation Research*, **2012**, 110, 1067-76	15.7	121
97	High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. *Nephrology Dialysis Transplantation*, **2012**, 27, 1793-800	4.3	47
96	A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy. *Expert Opinion on Drug Metabolism and Toxicology*, **2012**, 8, 1015-22	5.5	7
95	Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. *Journal of Hypertension*, **2012**, 30, 375-83	1.9	151
94	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. *Kidney International*, **2011**, 80, 282-7	9.9	217
93	Targeted reduction of advanced glycation improves renal function in obesity. *Kidney International*, **2011**, 80, 190-8	9.9	83
92	Osteoprotegerin promotes vascular fibrosis via a TGF-β autocrine loop. *Atherosclerosis*, **2011**, 218, 61-8	3.1	45
91	Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 537-44	12.7	83
90	Advanced glycation end products. *Contributions To Nephrology*, **2011**, 170, 66-74	1.6	50
89	New approaches to the treatment of nephropathy in diabetes. *Expert Opinion on Investigational Drugs*, **2011**, 20, 1057-71	5.9	13
88	Pathogenesis and progression of proteinuria. *Contributions To Nephrology*, **2011**, 170, 48-56	1.6	20
87	miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. *Diabetes*, **2011**, 60, 280-7	0.9	279

86	The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. *Diabetes Care*, **2011**, 34, 861-6	14.6	246
85	Bardoxolone: augmenting the Yin in chronic kidney disease. *Diabetes and Vascular Disease Research*, **2011**, 8, 303-4	3.3	2
84	Diabetes: bardoxolone improves kidney function in type 2 diabetes. *Nature Reviews Nephrology*, **2011**, 7, 552-3	14.9	12
83	Dietary salt intake and mortality in patients with type 2 diabetes. *Diabetes Care*, **2011**, 34, 703-9	14.6	228
82	Dedifferentiation of immortalized human podocytes in response to transforming growth factor-□a model for diabetic podocytopathy. *Diabetes*, **2011**, 60, 1779-88	0.9	97
81	Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. *Diabetes*, **2010**, 59, 3208-15	0.9	83
80	Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. *Circulation Research*, **2010**, 107, 888-97	15.7	179
79	The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. *Expert Reviews in Molecular Medicine*, **2010**, 12, e17	6.7	49
78	Cardiovascular disease: whatS's all the AGE/RAGE about?. *Cardiovascular & Hematological Disorders Drug Targets*, **2010**, 10, 7-15	1.1	28
77	Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. *Diabetes*, **2010**, 59, 3198-207	0.9	81
76	The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F528-35	4.3	34
75	High-salt diet reveals the hypertensive and renal effects of reduced nephron endowment. *American Journal of Physiology - Renal Physiology*, **2010**, 298, F1384-92	4.3	44
74	Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2010**, 298, F763-70	4.3	88
73	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. *Kidney International*, **2010**, 78, 287-95	9.9	58
72	Into the light? Diabetic nephropathy and vitamin D. *Lancet, The*, **2010**, 376, 1521-2	40	11
71	Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension. *Annals of Medicine*, **2010**, 42, 296-304	1.5	17
70	Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. *Journal of Hypertension*, **2010**, 28, 780-8	1.9	64
69	The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes*, **2009**, 58, 1651-8	0.9	410

68	Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). *Diabetes Care*, **2009**, 32, 1497-502	14.6	132
67	Low testosterone and anaemia in men with type 2 diabetes. *Clinical Endocrinology*, **2009**, 70, 547-53	3.4	47
66	Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. *Experimental Eye Research*, **2009**, 88, 1076-83	3.7	39
65	Direct antiatherosclerotic effects of PPAR agonists. *Current Opinion in Lipidology*, **2009**, 20, 24-9	4.4	25
64	Losing Control: Positive and Negative Feedback in the Renin Angiotensin System. *Current Hypertension Reviews*, **2009**, 5, 222-226	2.3	5
63	The assessment and management of albuminuria in primary care. *Diabetes Research and Clinical Practice*, **2008**, 80, 83-8	7.4	6
62	Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. *Diabetes*, **2008**, 57, 2461-9	0.9	334
61	PPAR Agonists and Cardiovascular Disease in Diabetes. *PPAR Research*, **2008**, 2008, 245410	4.3	22
60	Low testosterone levels are common and associated with insulin resistance in men with diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 1834-40	5.6	291
59	ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. *Diabetes*, **2008**, 57, 1018-25	0.9	147
58	Screening for chronic kidney disease in patients with diabetes: are we missing the point?. *Nature Clinical Practice Nephrology*, **2008**, 4, 2-3		12
57	Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 295, E323-30	6	83
56	Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. *Clinical Science*, **2008**, 114, 313-20	6.5	43
55	Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. *Cardiovascular Diabetology*, **2008**, 7, 15	8.7	11
54	Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus. *Journal of Medical Investigation*, **2008**, 55, 29-36	1.2	3
53	Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes. *Drug Discovery Today: Therapeutic Strategies*, **2007**, 4, 85-92		2
52	Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. *Medical Journal of Australia*, **2007**, 186, 128-30	4	11
51	The CARI guidelines. Prevention of progression of kidney disease: early detection of patients with kidney disease. *Nephrology*, **2007**, 12 Suppl 1, S37-40	2.2	6

50	The CARI guidelines. Prevention of progression of kidney disease: early referral of patients with pre-end-stage kidney disease. *Nephrology*, **2007**, 12 Suppl 1, S41-3	2.2	6
49	The CARI guidelines. Prevention of progression of kidney disease: regular and frequent follow-up of patients with pre-end-stage kidney disease. *Nephrology*, **2007**, 12 Suppl 1, S44-5	2.2	
48	The CARI guidelines. Prevention of progression of kidney disease: pre-dialysis education for patients with chronic kidney disease. *Nephrology*, **2007**, 12 Suppl 1, S46-8	2.2	9
47	The CARI guidelines. Prevention of progression of kidney disease: weight reduction in obese patients with chronic kidney disease. *Nephrology*, **2007**, 12 Suppl 1, S49-51	2.2	4
46	The CARI guidelines. Prevention of progression of kidney disease: autosomal-dominant polycystic kidney disease. *Nephrology*, **2007**, 12 Suppl 1, S52-6	2.2	2
45	The management of diabetes in indigenous Australians from primary care. *BMC Public Health*, **2007**, 7, 303	4.1	14
44	HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. *Diabetes Care*, **2007**, 30, 2706-7	14.6	22
43	Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. *Atherosclerosis*, **2007**, 195, 17-22	3.1	37
42	Anemia in diabetes: marker or mediator of microvascular disease?. *Nature Clinical Practice Nephrology*, **2007**, 3, 20-30		63
41	The epidemiology of hemoglobin levels in patients with type 2 diabetes. *American Journal of Kidney Diseases*, **2006**, 48, 537-45	7.4	59
40	Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. *Nephrology Dialysis Transplantation*, **2006**, 21, 1611-7	4.3	36
39	PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. *Nephrology Dialysis Transplantation*, **2006**, 21, 2399-405	4.3	89
38	Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 2484-94	12.7	218
37	Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?. *Diabetes Care*, **2006**, 29, 1560-6	14.6	102
36	Identification of obesity in patients with type 2 diabetes from Australian primary care: the NEFRON-5 study. *Diabetes Care*, **2006**, 29, 2723-5	14.6	10
35	Serum lipids and the progression of nephropathy in type 1 diabetes. *Diabetes Care*, **2006**, 29, 317-22	14.6	53
34	Blood pressure lowering for the prevention and treatment of diabetic kidney disease. *Drugs*, **2006**, 66, 2213-34	12.1	28
33	The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. *Seminars in Nephrology*, **2006**, 26, 275-82	4.8	33

32	The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). *Medical Journal of Australia*, **2006**, 185, 140-4	4	75
31	The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON-2). *Medical Journal of Australia*, **2006**, 185, 259-62	4	7
30	Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. *Clinical Science*, **2006**, 110, 109-16	6.5	37
29	Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. *Journal of Hypertension*, **2006**, 24, S57-63	1.9	34
28	The CARI guidelines. Prevention of progression of kidney disease. *Nephrology*, **2006**, 11 Suppl 1, S2-197	2.2	24
27	Analgesic-associated kidney disease. *Nephrology*, **2006**, 11, S123-S125	2.2	
26	Renal artery stenosis. *Nephrology*, **2006**, 11, S126-S131	2.2	
25	Specific management of IgA nephropathy: role of steroid therapy. *Nephrology*, **2006**, 11, S132-S136	2.2	
24	Specific management of IgA nephropathy: role of fish oil. *Nephrology*, **2006**, 11, S137-S140	2.2	
23	Specific management of IgA nephropathy: role of triple therapy and cytotoxic therapy. *Nephrology*, **2006**, 11, S141-S145	2.2	1
22	Specific management of IgA nephropathy: role of tonsillectomy. *Nephrology*, **2006**, 11, S146-S148	2.2	1
21	Specific management of IgA nephropathy: role of cyclosporin and other therapies. *Nephrology*, **2006**, 11, S149-S153	2.2	2
20	Membranous nephropathy: role of alkylating agents. *Nephrology*, **2006**, 11, S154-S161	2.2	
19	Membranous nephropathy: role of steroids. *Nephrology*, **2006**, 11, S162-S165	2.2	
18	Membranous nephropathy: role of cyclosporin therapy. *Nephrology*, **2006**, 11, S166-S169	2.2	
17	Treatment of secondary membranous nephropathy. *Nephrology*, **2006**, 11, S170-S171	2.2	
16	Idiopathic membranous nephropathy: use of other therapies. *Nephrology*, **2006**, 11, S172-S174	2.2	
15	Reflux nephropathy. *Nephrology*, **2006**, 11, S175-S181	2.2	

14	Focal segmental glomerulosclerosis: treatment with steroids. *Nephrology*, **2006**, 11, S182-S184	2.2	
13	Focal segmental glomerulosclerosis: use of cyclosporin A. *Nephrology*, **2006**, 11, S185-S188	2.2	
12	Focal segmental glomerulosclerosis: cytotoxic therapy. *Nephrology*, **2006**, 11, S189-S193	2.2	
11	Focal segmental glomerulosclerosis: correction of secondary causes. *Nephrology*, **2006**, 11, S194-S195	2.2	0
10	Focal segmental glomerulosclerosis: use of other therapies. *Nephrology*, **2006**, 11, S196-S197	2.2	
9	Anemia and Diabetic Nephropathy **2006**, 527-548		
8	Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2363-72	12.7	180
7	Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. *Kidney International*, **2005**, 68, 2756-65	9.9	18
6	Interactions between renin angiotensin system and advanced glycation in the kidney. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2976-84	12.7	118
5	Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. *Diabetes*, **2004**, 53, 989-97	0.9	233
4	Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. *Diabetes*, **2004**, 53, 1813-23	0.9	258
3	Reduced tubular cation transport in diabetes: prevented by ACE inhibition. *Kidney International*, **2003**, 63, 2152-61	9.9	46
2	Unrecognized anemia in patients with diabetes: a cross-sectional survey. *Diabetes Care*, **2003**, 26, 1164-9	14.6	232
1	Increased thrombotic vascular events after change of statin. *Lancet, The*, **1998**, 352, 1830-1	40	88